EP3187175 - SUPPLEMENTARY THERAPEUTIC FORMULATIONS FOR THE SEQUENTIAL OR SEPARATE ADMINISTRATION OF BUTYRIC ACID AND PROBIOTICS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 04.02.2022 Database last updated on 02.09.2024 | |
Former | The patent has been granted Status updated on 26.02.2021 | ||
Former | Grant of patent is intended Status updated on 21.10.2020 | ||
Former | Request for examination was made Status updated on 05.01.2018 | ||
Former | The application has been published Status updated on 02.06.2017 | Most recent event Tooltip | 27.04.2024 | Lapse of the patent in a contracting state New state(s): MK | published on 29.05.2024 [2024/22] | Applicant(s) | For all designated states Euro-Pharma S.r.l. Via Garzigliana, 8 10127 Torino / IT | [2021/13] |
Former [2017/27] | For all designated states Euro-Pharma S.r.l. Via Garzigliana, 8 10127 Torino / IT | Inventor(s) | 01 /
MISCIOSCIA, Mario deceased / IT | [2021/24] |
Former [2017/27] | 01 /
MISCIOSCIA, Mario Via Garzigliana 8 10127 TORINO / IT | Representative(s) | Coppo, Alessandro, et al Notarbartolo & Gervasi S.p.A. Viale Achille Papa, 30 20149 Milano / IT | [2021/13] |
Former [2017/27] | Brighenti, Livio, et al NOTARBARTOLO & GERVASI S.p.A. Corso di Porta Vittoria, 9 20122 Milano / IT | Application number, filing date | 16206400.0 | 22.12.2016 | [2017/27] | Priority number, date | IT2015UB09138 | 22.12.2015 Original published format: IT UB20159138 | [2017/27] | Filing language | IT | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3187175 | Date: | 05.07.2017 | Language: | EN | [2017/27] | Type: | B1 Patent specification | No.: | EP3187175 | Date: | 31.03.2021 | Language: | EN | [2021/13] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 02.06.2017 | Classification | IPC: | A61K31/19, A61K9/20, A61K9/48, A61K35/745, A61K9/16, A61K9/28, A61P1/00, A61K36/752 | [2020/46] | CPC: |
A61K9/2013 (EP);
A23L33/105 (EP);
A23L33/12 (EP);
A23L33/135 (EP);
A23L33/21 (EP);
A61K31/19 (EP);
A61K35/745 (EP);
A61K35/747 (EP);
A61K36/752 (EP);
A61K9/1664 (EP);
A61K9/2866 (EP);
A61K9/288 (EP);
| C-Set: |
A61K31/19, A61K2300/00 (EP);
A61K36/752, A61K2300/00 (EP);
A23V2002/00, A23V2200/3202, A23V2200/3204, A23V2250/284 (EP)
|
Former IPC [2020/45] | A61K9/20, A61K9/48, A61K35/745, A61K9/16, A61K9/28, A61P1/00 | ||
Former IPC [2017/27] | A61K9/20, A61K9/48, A61K35/745, A61K9/16, A61K9/28 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/06] |
Former [2017/27] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | ZUSÄTZLICHE THERAPEUTISCHE FORMULIERUNGEN ZUR SEQUENZIELLEN ODER SEPARATEN VERABREICHUNG VON BUTTERSÄURE UND PROBIOTIKA | [2017/27] | English: | SUPPLEMENTARY THERAPEUTIC FORMULATIONS FOR THE SEQUENTIAL OR SEPARATE ADMINISTRATION OF BUTYRIC ACID AND PROBIOTICS | [2017/27] | French: | FORMULATIONS THÉRAPEUTIQUES SUPPLÉMENTAIRES POUR L'ADMINISTRATION SÉQUENTIELLE OU SÉPARÉE D'ACIDE BUTYRIQUE ET PROBIOTIQUES | [2017/27] | Examination procedure | 22.12.2016 | Date on which the examining division has become responsible | 21.12.2017 | Amendment by applicant (claims and/or description) | 21.12.2017 | Examination requested [2018/06] | 22.10.2020 | Communication of intention to grant the patent | 22.02.2021 | Fee for grant paid | 22.02.2021 | Fee for publishing/printing paid | 22.02.2021 | Receipt of the translation of the claim(s) | Opposition(s) | 04.01.2022 | No opposition filed within time limit [2022/10] | Fees paid | Renewal fee | 21.12.2018 | Renewal fee patent year 03 | 31.12.2019 | Renewal fee patent year 04 | 31.12.2020 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 22.12.2016 | AT | 31.03.2021 | CZ | 31.03.2021 | DK | 31.03.2021 | EE | 31.03.2021 | FI | 31.03.2021 | HR | 31.03.2021 | LT | 31.03.2021 | LV | 31.03.2021 | MC | 31.03.2021 | MK | 31.03.2021 | NL | 31.03.2021 | RO | 31.03.2021 | RS | 31.03.2021 | SE | 31.03.2021 | SI | 31.03.2021 | SK | 31.03.2021 | SM | 31.03.2021 | NO | 30.06.2021 | IS | 31.07.2021 | PT | 02.08.2021 | IE | 22.12.2021 | LU | 22.12.2021 | BE | 31.12.2021 | [2024/22] |
Former [2023/27] | HU | 22.12.2016 | |
AT | 31.03.2021 | ||
CZ | 31.03.2021 | ||
DK | 31.03.2021 | ||
EE | 31.03.2021 | ||
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
MC | 31.03.2021 | ||
NL | 31.03.2021 | ||
RO | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SI | 31.03.2021 | ||
SK | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
IS | 31.07.2021 | ||
PT | 02.08.2021 | ||
IE | 22.12.2021 | ||
LU | 22.12.2021 | ||
BE | 31.12.2021 | ||
Former [2023/01] | AT | 31.03.2021 | |
CZ | 31.03.2021 | ||
DK | 31.03.2021 | ||
EE | 31.03.2021 | ||
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
MC | 31.03.2021 | ||
NL | 31.03.2021 | ||
RO | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SI | 31.03.2021 | ||
SK | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
IS | 31.07.2021 | ||
PT | 02.08.2021 | ||
IE | 22.12.2021 | ||
LU | 22.12.2021 | ||
BE | 31.12.2021 | ||
Former [2022/48] | AT | 31.03.2021 | |
CZ | 31.03.2021 | ||
DK | 31.03.2021 | ||
EE | 31.03.2021 | ||
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
MC | 31.03.2021 | ||
NL | 31.03.2021 | ||
RO | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SI | 31.03.2021 | ||
SK | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
IS | 31.07.2021 | ||
PT | 02.08.2021 | ||
IE | 22.12.2021 | ||
LU | 22.12.2021 | ||
Former [2022/46] | AT | 31.03.2021 | |
CZ | 31.03.2021 | ||
DK | 31.03.2021 | ||
EE | 31.03.2021 | ||
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
MC | 31.03.2021 | ||
NL | 31.03.2021 | ||
RO | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SI | 31.03.2021 | ||
SK | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
IS | 31.07.2021 | ||
PT | 02.08.2021 | ||
LU | 22.12.2021 | ||
Former [2022/33] | AT | 31.03.2021 | |
CZ | 31.03.2021 | ||
DK | 31.03.2021 | ||
EE | 31.03.2021 | ||
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
MC | 31.03.2021 | ||
NL | 31.03.2021 | ||
RO | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SI | 31.03.2021 | ||
SK | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
IS | 31.07.2021 | ||
PT | 02.08.2021 | ||
Former [2022/29] | AT | 31.03.2021 | |
CZ | 31.03.2021 | ||
DK | 31.03.2021 | ||
EE | 31.03.2021 | ||
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
NL | 31.03.2021 | ||
RO | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SI | 31.03.2021 | ||
SK | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
IS | 31.07.2021 | ||
PT | 02.08.2021 | ||
Former [2022/23] | AT | 31.03.2021 | |
CZ | 31.03.2021 | ||
DK | 31.03.2021 | ||
EE | 31.03.2021 | ||
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
NL | 31.03.2021 | ||
RO | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SK | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
IS | 31.07.2021 | ||
PT | 02.08.2021 | ||
Former [2022/10] | AT | 31.03.2021 | |
CZ | 31.03.2021 | ||
DK | 31.03.2021 | ||
EE | 31.03.2021 | ||
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
NL | 31.03.2021 | ||
RO | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SK | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
PT | 02.08.2021 | ||
IS | 24.12.2021 | ||
Former [2022/08] | AT | 31.03.2021 | |
CZ | 31.03.2021 | ||
DK | 31.03.2021 | ||
EE | 31.03.2021 | ||
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
NL | 31.03.2021 | ||
RO | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SK | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
IS | 31.07.2021 | ||
PT | 02.08.2021 | ||
Former [2021/51] | AT | 31.03.2021 | |
CZ | 31.03.2021 | ||
EE | 31.03.2021 | ||
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
NL | 31.03.2021 | ||
RO | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SK | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
IS | 31.07.2021 | ||
PT | 02.08.2021 | ||
Former [2021/50] | AT | 31.03.2021 | |
CZ | 31.03.2021 | ||
EE | 31.03.2021 | ||
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
NL | 31.03.2021 | ||
RO | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SK | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
PT | 02.08.2021 | ||
Former [2021/48] | AT | 31.03.2021 | |
CZ | 31.03.2021 | ||
EE | 31.03.2021 | ||
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
NL | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
Former [2021/47] | AT | 31.03.2021 | |
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
NL | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
Former [2021/46] | AT | 31.03.2021 | |
FI | 31.03.2021 | ||
HR | 31.03.2021 | ||
LT | 31.03.2021 | ||
LV | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
SM | 31.03.2021 | ||
NO | 30.06.2021 | ||
Former [2021/38] | FI | 31.03.2021 | |
HR | 31.03.2021 | ||
LV | 31.03.2021 | ||
RS | 31.03.2021 | ||
SE | 31.03.2021 | ||
NO | 30.06.2021 | ||
Former [2021/37] | FI | 31.03.2021 | |
HR | 31.03.2021 | ||
LV | 31.03.2021 | ||
RS | 31.03.2021 | ||
NO | 30.06.2021 | ||
Former [2021/35] | FI | 31.03.2021 | |
HR | 31.03.2021 | ||
NO | 30.06.2021 | ||
Former [2021/33] | FI | 31.03.2021 | |
NO | 30.06.2021 | Documents cited: | Search | [YA]EP1236466 (EFRAT BIOPOLYMERS LTD [IL]) [Y] 14 * paragraph [0084] * [A] 1-13; | [YA]WO2005074718 (COSMO SPA [IT], et al) [Y] 14 * page 7, line 12 - line 19 * * example - * [A] 1-13; | [A]WO2007125558 (ANIDRAL SRL [IT], et al) [A] 1-14 * page 1, line 1 - page 4, line 6 * * page 11, line 8 - page 17, line 17 * * page 21, line 5 - page 23, line 4 *; | [YA]EP2289505 (ALPIFLOR S R L [IT]) [Y] 14 * the whole document * [A] 1-13; | [YA]WO2012013495 (COSMO TECHNOLOGIES LTD [IE], et al) [Y] 14 * the whole document * [A] 1-13; | [A]WO2014152338 (KABADI MOHAN [US], et al) [A] 1-14 * page 4, line 4 - line 18 * * page 36, line 14 - page 42, line 9 *; | [YA] - LEE TAE-HO ET AL, "The Inhibitory Effect of Grapefruit Seed Extracts on the Physiological Function of Enterobacter pyrinus", KOREAN JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, SEOUL, KR, (19951231), vol. 27, no. 6, ISSN 0367-6293, pages 985 - 990, XP053022952 [Y] 14 * the whole document * [A] 1-13 | by applicant | WO2013114185 |